235 related articles for article (PubMed ID: 26739671)
1. Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence.
Grüllich C; Vallet S; Hecht C; Duensing S; Hadaschik B; Jäger D; Hohenfellner M; Pahernik S
Urol Oncol; 2016 May; 34(5):238.e9-17. PubMed ID: 26739671
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
3. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
4. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent change in relapse sites of renal cell carcinoma after curative surgery.
Noguchi G; Nakaigawa N; Taguri M; Tsutsumi S; Saito Y; Fukui S; Yasui M; Tokita T; Mitome T; Tatenuma T; Kuroda S; Abe K; Ueno D; Namura K; Umemoto S; Takizawa A; Ohta J; Ueki T; Watanabe T; Kobayashi K; Kondo K; Kishida T; Kanno H; Kitami K; Yamanaka T; Yao M
Clin Exp Metastasis; 2018 Feb; 35(1-2):69-75. PubMed ID: 29516208
[TBL] [Abstract][Full Text] [Related]
7. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
11. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
13. The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.
Steiner T; Kirchner H; Siebels M; Doehn C; Heynemann H; Varga Z; Rohde D; Schubert J; Jocham D; Stief C; Fornara P; Hofmann R; Loening S; Roigas J
J Cancer Res Clin Oncol; 2010 Jun; 136(6):905-10. PubMed ID: 20012752
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: how and when?
Liao CT; Chang JT; Wang HM; Ng SH; Hsueh C; Lee LY; Lin CH; Chen IH; Huang SF; Cheng AJ; Yen TC
Cancer; 2008 Jan; 112(1):94-103. PubMed ID: 18022917
[TBL] [Abstract][Full Text] [Related]
15. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
Park YH; Baik KD; Lee YJ; Ku JH; Kim HH; Kwak C
BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma.
Hallemeier CL; Choo R; Davis BJ; Pisansky TM; Gunderson LL; Leibovich BC; Haddock MG
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1938-43. PubMed ID: 21514065
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O; Inanc M; Hacibekıroglu I; Esbah O; Seker M; Ulas A; Aydin K; Uysal M; Kücüköner M; Uncu D; Cıltas A; Unal OÜ; Durnali A; Demırcı U; Berk V; Tonyali O; Oksüzoglu B; Karaca H; Ozkan M
Anticancer Res; 2014 Aug; 34(8):4463-70. PubMed ID: 25075086
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
Matrana MR; Baiomy A; Campbell M; Alamri S; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Elsayes KM; Tannir NM
Clin Genitourin Cancer; 2017 Apr; 15(2):e205-e208. PubMed ID: 27568124
[TBL] [Abstract][Full Text] [Related]
19. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
20. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
